Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs for Tourette Syndrome
NCT05158439Phase 1Withdrawn
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Jan 2022
- Primary completion
- Jan 2026
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord derived mesenchymal stem cells in Tourette syndrome (TS), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 48 months. Planned start Jan 2022; status: withdrawn.
02
Drugs
human umbilical cord derived mesenchymal stem cells
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT05158439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05158439.